Advaxis Inc. buy melinda
Start price
11.09.18
/
50%
€11.67
Target price
23.01.19
€18.94
Performance (%)
-62.22%
End price
23.01.19
€4.41
Summary
This prediction ended on 23.01.19 with a price of €4.41. Massive losses of -62.22% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Advaxis Inc. | - | - | - | - |
| iShares Core DAX® | 1.080% | -2.933% | 12.885% | 14.247% |
| iShares Nasdaq 100 | 0.362% | 7.015% | 36.826% | 57.151% |
| iShares Nikkei 225® | -1.155% | -1.155% | 5.073% | 3.799% |
| iShares S&P 500 | 0.806% | 4.388% | 30.269% | 49.772% |
Comments by melinda for this prediction
In the thread Advaxis Inc. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 19/12 Publication de résultats
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of cancer immunotherapies.
It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins.
It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy, and hotspot mutation therapy.
The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.
Nombre d'employés : 108 personnes.
(Vom Mitglied beendet)